Eisai Announces New Data on LEQEMBI® Subcutaneous Formulation Demonstrating Enhanced Amyloid Clearance and Potential for At-Home Administration

On October 26, Eisai announced at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting the interim research results of the 100mg/mL subcutaneous injection version of its AD treatment drug LEQEMBI® (lecanemab-irmb), as well as clinical improvement data for the early stages of AD.

Image Source: Eisai Official Website

According to the report, after six months of treatment, the once-weekly subcutaneous (SC) injection version of the drug showed a 14% higher ability to clear amyloid compared to the currently marketed version; the blood concentration of the SC version was 11% higher than other versions; and the systemic injection reaction rate of the SC version was lower. However, the incidence of side effects such as brain swelling and bleeding was similar between the two versions.

Eisai Plans to Submit the Biologics License Application (BLA) for LEQEMBISC to the FDA by March 31, 2024.

At the same time, Eisai also announced the relevant data of its TauPet longitudinal study and sub-study:

Source of the image: Eisai's official website

In addition, according to Zhitong Finance, the new version of Leqembi might allow for at-home injections.

Source of the image: Zhitong Finance Official Website

Editor: Muyan

Disclaimer: This article is a reprint from PharmNet. The images and text are owned by the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.